XLS Stock Overview
Focuses on the development and commercialization of technologies in the life sciences sector.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xlife Sciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF33.20 |
| 52 Week High | CHF51.40 |
| 52 Week Low | CHF31.50 |
| Beta | 0.43 |
| 1 Month Change | -0.30% |
| 3 Month Change | -28.45% |
| 1 Year Change | -12.40% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.22% |
Recent News & Updates
Shareholder Returns
| XLS | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | -6.2% | 0.6% | 1.5% |
| 1Y | -12.4% | -9.1% | 1.7% |
Return vs Industry: XLS underperformed the Swiss Life Sciences industry which returned -9.1% over the past year.
Return vs Market: XLS underperformed the Swiss Market which returned 1.7% over the past year.
Price Volatility
| XLS volatility | |
|---|---|
| XLS Average Weekly Movement | 8.5% |
| Life Sciences Industry Average Movement | 4.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.1% |
| 10% least volatile stocks in CH Market | 1.8% |
Stable Share Price: XLS's share price has been volatile over the past 3 months.
Volatility Over Time: XLS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 17 | Oliver Baumann | www.xlifesciences.ch |
Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company’s project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases.
Xlife Sciences AG Fundamentals Summary
| XLS fundamental statistics | |
|---|---|
| Market cap | CHF189.35m |
| Earnings (TTM) | CHF14.88m |
| Revenue (TTM) | CHF988.44k |
12.7x
P/E Ratio191.6x
P/S RatioIs XLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XLS income statement (TTM) | |
|---|---|
| Revenue | CHF988.44k |
| Cost of Revenue | CHF539.42k |
| Gross Profit | CHF449.02k |
| Other Expenses | -CHF14.43m |
| Earnings | CHF14.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | 2.61 |
| Gross Margin | 45.43% |
| Net Profit Margin | 1,505.34% |
| Debt/Equity Ratio | 15.5% |
How did XLS perform over the long term?
See historical performance and comparison